Sprint Bioscience lands $93,800 Vinnova grant for drug discovery research

What's the deal? Sprint BioscienceDealroom has a profile for this one. Try Dealroom →, a Stockholm-based oncology drug developer, has been awarded roughly US$113.6K from Swedish innovation agency VinnovaDealroom has a profile for this one. Try Dealroom →. The grant backs a joint research initiative with MAX IVDealroom has a profile for this one. Try Dealroom →, a national research facility, focused on alternative methods for fragment screening in drug discovery.

What's the endgame? The partners will study how temperature affects the way small-molecule fragments bind to target proteins — the starting points for Sprint's programs. The work compares fragment screening under cryogenic and room-temperature conditions to see whether room-temperature studies yield more biologically relevant insights.

The project runs from November 2026 to October 2028. Of the total award, Sprint may receive up to roughly US$85.1K, with the remainder supporting MAX IV's capacity to offer room-temperature data collection for industrial users.

Why it matters: Sprint develops small-molecule, first-in-class programs using a fragment-based method it says is time- and resource-efficient, licensing them to larger pharmaceutical firms in the pre-clinical phase.

Chief executive officer Johan Emilsson called the decision "a clear recognition of the expertise and scientific capabilities that Sprint Bioscience has built within fragment-based drug discovery." He said the collaboration offers "an opportunity to explore new approaches that could strengthen future drug discovery programs."

The signal: The grant is modest — among the smaller funding events on record — but it keeps Sprint, listed on Nasdaq First North Premier Growth Market, investing in the core screening technology its licensing model depends on while deepening ties to Sweden's research infrastructure.

Read more: ae.marketscreener.com

Image credit: zhouxuan12345678